Trump's Psychedelic Power Play: White House Races To Boost Ibogaine Research

President Trump is poised to put a little-known psychedelic on Washington’s to-do list, with an executive order expected in the coming days that would push federal agencies to study ibogaine, a plant-derived compound some veterans and researchers say can help with treatment-resistant PTSD. The move would crack open the door to U.S.-funded clinical trials even though ibogaine is still illegal nationwide, reflecting mounting pressure from states and advocacy groups to put controversial therapies through large, formal tests. Scientists say the early data are intriguing but limited, and clinicians are quick to flag serious heart risks.

White House move and what it would do

The administration is drafting an order that would signal the White House is ready to back research on ibogaine, with the president possibly signing as soon as this week, according to CBS News. That reporting describes a directive aimed at unlocking federal funding and coordination across agencies rather than immediately changing the drug’s legal status. White House spokespeople did not immediately comment on the draft order.

Where ibogaine stands under federal law

For now, ibogaine sits in the same legal bucket as other Schedule I substances, the category the federal government uses for drugs it says have “no currently accepted medical use” and a high potential for abuse. That designation sharply restricts clinical access and makes research a bureaucratic slog. The listing and examples appear in federal practitioner guidance and scheduling materials, which is one reason advocates are pressing for tightly controlled, federally supervised trials. DEA Practitioner Manual

The evidence so far

Much of the current buzz traces back to small, early-stage work. A Stanford-led, open-label study of 30 veterans published in Nature Mental Health reported large, short-term improvements in PTSD symptoms, depression and cognitive function after a single dose of magnesium-protected ibogaine. Stanford Medicine later summarized the findings for a broader audience. The authors, along with outside researchers, have repeatedly stressed that while the results look promising, randomized, placebo-controlled trials are still needed to test safety and durability of any benefit.

Safety and scientific caution

A 2022 systematic review in the Journal of Substance Abuse Treatment pooled 24 studies covering about 700 people and found that ibogaine appeared to reduce withdrawal symptoms and cravings, with signals of improvement in mood and trauma-related symptoms. The same review, however, highlighted cardiac toxicity and reported fatalities linked to unsupervised use. Researchers and clinicians underscore that these heterogeneous, mostly non-randomized studies fall well short of the large, carefully controlled trials regulators typically expect before greenlighting routine medical use.

Who’s pushing this

The political energy behind ibogaine is an unusual mix of veteran advocates, conservative officials and media personalities. Former Texas governor Rick Perry and activists including W. Bryan Hubbard have publicly campaigned for the drug and discussed it on podcasts such as The Joe Rogan Experience. At the state level, Texas has already earmarked roughly $50 million for clinical trials and public-private research partnerships focused on ibogaine and related treatments. Office of Gov. Greg Abbott

Legal hurdles and next steps

Actually rescheduling ibogaine or approving it for routine medical use would require formal review by the Department of Health and Human Services and the Drug Enforcement Administration or an act of Congress. Lawmakers have already floated proposals such as the bipartisan “Freedom to Heal Act,” which would create a special registration pathway for Schedule I investigational drugs. Congress.gov The executive order can speed up funding and interagency cooperation, but on its own it cannot remove ibogaine from Schedule I, so any path to mainstream medical use still runs through rulemaking, formal trials and regulatory review.

What comes next will hinge on the final text of the order, including which agencies get marching orders and money, and what safety standards they insist on. Watch for whether NIH, the VA or HHS roll out specific trials or grant programs, and how Texas and other states line up their own funded research with federal regulators. Early national coverage of the expected White House move surfaced via major outlets including CNN Newsource.